Published in Biomark Med on June 01, 2009
A candidate molecular biomarker panel for the detection of bladder cancer. Cancer Epidemiol Biomarkers Prev (2012) 1.10
IL-8 as a urinary biomarker for the detection of bladder cancer. BMC Urol (2012) 1.09
Methylation markers for urine-based detection of bladder cancer: the next generation of urinary markers for diagnosis and surveillance of bladder cancer. Adv Urol (2012) 0.90
Molecular diagnostic trends in urological cancer: biomarkers for non-invasive diagnosis. Curr Med Chem (2012) 0.83
Epigenetic regulation of Elf5 is associated with epithelial-mesenchymal transition in urothelial cancer. PLoS One (2015) 0.82
Interaction network analysis of differentially expressed genes and screening of cancer marker in the urine of patients with invasive bladder cancer. Int J Clin Exp Med (2015) 0.80
The expression of AEG-1 and Cyclin D1 in human bladder urothelial carcinoma and their clinicopathological significance. Int J Clin Exp Med (2015) 0.75
New and contemporary markers of prognosis in nonmuscle invasive urothelial cancer. Korean J Urol (2015) 0.75
Diagnostic significance of microRNAs as novel biomarkers for bladder cancer: a meta-analysis of ten articles. World J Surg Oncol (2017) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science (1999) 83.27
Identification of a nuclear protein matrix. Biochem Biophys Res Commun (1974) 5.41
Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol (2006) 5.10
Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol (2007) 5.03
The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics (2003) 4.99
Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res (2002) 4.42
Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet (2002) 3.82
Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res (2004) 3.76
In silico dissection of cell-type-associated patterns of gene expression in prostate cancer. Proc Natl Acad Sci U S A (2004) 3.65
Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA (2006) 3.41
Clinical practice. Microscopic hematuria. N Engl J Med (2003) 2.96
Detection of bladder cancer using a point-of-care proteomic assay. JAMA (2005) 2.88
Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol (2000) 2.38
Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res (2005) 2.29
Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology (2005) 2.10
Improved breast cancer prognosis through the combination of clinical and genetic markers. Bioinformatics (2006) 1.93
Urine markers for bladder cancer surveillance: a systematic review. Eur Urol (2005) 1.90
Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol (2003) 1.86
Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res (2005) 1.85
A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol (2000) 1.81
Rapid detection of bladder cancer: a comparative study of point of care tests. J Urol (1997) 1.80
The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn (2000) 1.74
Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res (2007) 1.68
Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling. J Proteome Res (2007) 1.62
Analysis of genetic alterations in normal bladder urothelium. Urology (2003) 1.52
Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol (2002) 1.48
Bladder cancer-associated gene expression signatures identified by profiling of exfoliated urothelia. Cancer Epidemiol Biomarkers Prev (2009) 1.37
Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst (2003) 1.31
Tumor-associated hyaluronan. Providing an extracellular matrix that facilitates invasion. Am J Pathol (1996) 1.29
A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin Cancer Res (2005) 1.28
Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer. Cancer Res (1997) 1.28
Molecular profiling of ADAM12 in human bladder cancer. Clin Cancer Res (2006) 1.26
Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer. Acta Cytol (1993) 1.22
Urinary tract infection and patient satisfaction after flexible cystoscopy and urodynamic evaluation. Urology (2000) 1.18
Profiling bladder cancer using targeted antibody arrays. Am J Pathol (2006) 1.17
Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology (1998) 1.17
Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int (2006) 1.12
Current status of urinary cytology in the evaluation of bladder neoplasms. Hum Pathol (1990) 1.08
Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol (2005) 1.07
Urine cytology of transitional cell neoplasms. Urol Clin North Am (1979) 1.06
Bladder cancer. Clinical guidelines in oncology. J Natl Compr Canc Netw (2006) 1.04
Screening and monitoring for bladder cancer: refining the use of NMP22. J Urol (2001) 1.02
Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology (1997) 1.00
Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer. Cancer Res (1997) 0.97
Use of urinary biomarkers for bladder cancer surveillance: patient perspectives. J Urol (2007) 0.92
A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy. BJU Int (2009) 0.92
Differential expression of ribosomal proteins in a human metastasis model identified by coupling 2-D liquid chromatography and mass spectrometry. Cancer Genomics Proteomics (2007) 0.85
Voided urinary cytology in bladder cancer: is it time to review the indications? Urology (2007) 0.84
HA-HAase urine test. A sensitive and specific method for detecting bladder cancer and evaluating its grade. Urol Clin North Am (2000) 0.82
Diagnostic accuracy of urinary cytology, and deoxyribonucleic acid flow cytometry and cytology on bladder washings during followup for bladder tumors. J Urol (1997) 0.81
The application of human complement factor H-related protein (BTA TRAK) in monitoring patients with bladder cancer. Urol Clin North Am (2000) 0.81
Comparison of BTA stat and NMP22 tests in the detection of bladder cancer. Scand J Urol Nephrol (2000) 0.79
[Hyaluronic acid and hyaluronidase. 2 new bladder carcinoma markers]. Urologe A (2001) 0.78
Qualitative determination of urinary human complement factor H-related protein (hcfHrp) in patients with bladder cancer, healthy controls, and patients with benign urologic disease. Urol Int (2000) 0.78
Utility of the BTA stat test kit for bladder cancer screening. Diagn Cytopathol (1999) 0.77
Utility of the Bard BTA test in detecting upper urinary tract transitional cell carcinoma. Urology (1998) 0.76
Diagnostic potential of urinary α1-antitrypsin and apolipoprotein E in the detection of bladder cancer. J Urol (2012) 2.12
Improved breast cancer prognosis through the combination of clinical and genetic markers. Bioinformatics (2006) 1.93
Diagnosis of prostate cancer using differentially expressed genes in stroma. Cancer Res (2011) 1.78
Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation. Prostate (2008) 1.74
Comprehensive karyotyping of the HT-29 colon adenocarcinoma cell line. Genes Chromosomes Cancer (2002) 1.64
Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling. J Proteome Res (2007) 1.62
Persistent exposure to Mycoplasma induces malignant transformation of human prostate cells. PLoS One (2009) 1.57
Protein kinase D1 regulates matrix metalloproteinase expression and inhibits breast cancer cell invasion. Breast Cancer Res (2009) 1.55
Pheochromocytoma of the urinary bladder: a systematic review of the contemporary literature. BMC Urol (2013) 1.52
Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification. Clin Cancer Res (2011) 1.50
Advanced computational algorithms for microbial community analysis using massive 16S rRNA sequence data. Nucleic Acids Res (2010) 1.50
Imaging the urologic patient: the utility of intravenous pyelogram in the CT scan era. World J Urol (2013) 1.47
Contrasting expression of thrombospondin-1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis. Clin Cancer Res (2002) 1.45
Total pelvic exenteration: effective palliation of perineal pain in patients with locally recurrent prostate cancer. J Urol (2003) 1.41
The use of enoxaparin to prevent venous thromboembolism in patients undergoing radical retropubic prostatectomy: feasibility and utility. Int Braz J Urol (2007) 1.38
Bladder cancer-associated gene expression signatures identified by profiling of exfoliated urothelia. Cancer Epidemiol Biomarkers Prev (2009) 1.37
Young age is an independent prognostic factor for survival of sporadic renal cell carcinoma. J Urol (2004) 1.36
Tumor-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway. Cancer Res (2011) 1.34
Local-learning-based feature selection for high-dimensional data analysis. IEEE Trans Pattern Anal Mach Intell (2010) 1.31
Optimizing molecular signatures for predicting prostate cancer recurrence. Prostate (2009) 1.22
p37 Induces tumor invasiveness. Mol Cancer Ther (2005) 1.21
Membrane glycoproteins associated with breast tumor cell progression identified by a lectin affinity approach. J Proteome Res (2008) 1.21
Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer. Cancer (2006) 1.20
Comprehensive assessment of quality of life and psychosocial adjustment in patients with renal tumors undergoing open, laparoscopic and nephron sparing surgery. J Urol (2012) 1.19
CCL18 in a multiplex urine-based assay for the detection of bladder cancer. PLoS One (2012) 1.18
Structure determination of the cancer-associated Mycoplasma hyorhinis protein Mh-p37. Acta Crystallogr D Biol Crystallogr (2008) 1.17
An invasion-independent pathway of blood-borne metastasis: a new murine mammary tumor model. Am J Pathol (2002) 1.14
Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. Prostate (2009) 1.14
Utility of serial urinary cytology in the initial evaluation of the patient with microscopic hematuria. BMC Urol (2009) 1.14
Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts. Mol Cancer Ther (2007) 1.11
A novel aptamer developed for breast cancer cell internalization. ChemMedChem (2011) 1.10
Smoothelin immunohistochemistry is a useful adjunct for assessing muscularis propria invasion in bladder carcinoma. Histopathology (2010) 1.10
A multi-analyte assay for the non-invasive detection of bladder cancer. PLoS One (2012) 1.10
A candidate molecular biomarker panel for the detection of bladder cancer. Cancer Epidemiol Biomarkers Prev (2012) 1.10
IL-8 as a urinary biomarker for the detection of bladder cancer. BMC Urol (2012) 1.09
Expression of CXCL1 in human endothelial cells induces angiogenesis through the CXCR2 receptor and the ERK1/2 and EGF pathways. Lab Invest (2013) 1.07
Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary biomarkers for bladder cancer detection. Urology (2012) 1.06
Expression of matrix metalloproteinase 8 (MMP-8) and tyrosinase-related protein-1 (TYRP-1) correlates with the absence of metastasis in an isogenic human breast cancer model. Differentiation (2003) 1.06
Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC Cancer (2008) 1.05
Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status. Breast Cancer Res (2003) 1.04
Detection of antibodies directed at M. hyorhinis p37 in the serum of men with newly diagnosed prostate cancer. BMC Cancer (2011) 1.02
Paper based point-of-care testing disc for multiplex whole cell bacteria analysis. Biosens Bioelectron (2011) 1.02
Structural insights into the extracytoplasmic thiamine-binding lipoprotein p37 of Mycoplasma hyorhinis. J Bacteriol (2009) 1.02
Multiplex protein signature for the detection of bladder cancer in voided urine samples. J Urol (2013) 1.01
Identification of metastasis-associated proteins in a human tumor metastasis model using the mass-mapping technique. Proteomics (2004) 1.00
Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers. BMC Cancer (2013) 0.99
Syk tyrosine kinase acts as a pancreatic adenocarcinoma tumor suppressor by regulating cellular growth and invasion. Am J Pathol (2009) 0.98
Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model. Mol Cancer Ther (2013) 0.98
Prognostic value of body mass index in patients undergoing nephrectomy for localized renal tumors. Urology (2004) 0.97
An intronic mutation causes long QT syndrome. J Am Coll Cardiol (2004) 0.97
Bladder cancer detection and monitoring: assessment of urine- and blood-based marker tests. Mol Diagn Ther (2013) 0.96
Immunohistochemical detection of hTERT in urothelial lesions: a potential adjunct to urine cytology. Cytojournal (2006) 0.96
Morphological evidence for an invasion-independent metastasis pathway exists in multiple human cancers. BMC Med (2004) 0.94
Influencing factors on the NMP-22 urine assay: an experimental model. BMC Urol (2012) 0.94
Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation. Mol Cancer Ther (2008) 0.94
Noninvasive detection of bladder cancer in an orthotopic murine model with green fluorescence protein cytology. J Urol (2003) 0.94
Design of a carbonic anhydrase IX active-site mimic to screen inhibitors for possible anticancer properties. Biochemistry (2009) 0.93
Combination of PTEN gene therapy and radiation inhibits the growth of human prostate cancer xenografts. Hum Gene Ther (2006) 0.91
Analysis of G/A polymorphism in the androgen response element I of the PSA gene and its interactions with the androgen receptor polymorphisms. Urology (2003) 0.90
Blunt apical dissection during anatomic radical retropubic prostatectomy. BMC Res Notes (2009) 0.90
Downregulation of BCL-2 induces downregulation of carbonic anhydrase IX, vascular endothelial growth factor, and pAkt and induces radiation sensitization. Urology (2007) 0.89
Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer. J Urol (2005) 0.89
Telomerase reverse transcriptase promoter regulation during myogenic differentiation of human RD rhabdomyosarcoma cells. Mol Cancer Res (2003) 0.89
Matrix metalloproteinase-10 promotes tumor progression through regulation of angiogenic and apoptotic pathways in cervical tumors. BMC Cancer (2014) 0.89
Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation. World J Urol (2008) 0.89
Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer. Cancer Gene Ther (2002) 0.87
Positive surgical margins at radical prostatectomy: importance of intra-operative bladder neck frozen sections. Int Braz J Urol (2008) 0.87
Proteomic profiling identifies breast tumor metastasis-associated factors in an isogenic model. Proteomics (2007) 0.87
Neoadjuvant therapy before radical prostatectomy: where have we been? Where are we going? Urol Oncol (2007) 0.87
Locally advanced paraganglioma of the urinary bladder: a case report. BMC Res Notes (2013) 0.86
Bcl-2 mediated modulation of vascularization in prostate cancer xenografts. Prostate (2009) 0.86
Enrichment of glycoproteins using nanoscale chelating concanavalin A monolithic capillary chromatography. Anal Chem (2009) 0.86
Focal cryosurgical ablation of the prostate: a single institute's perspective. BMC Urol (2013) 0.85
Visualizing superficial human bladder cancer cell growth in vivo by green fluorescent protein expression. Cancer Gene Ther (2002) 0.85
Differential expression of ribosomal proteins in a human metastasis model identified by coupling 2-D liquid chromatography and mass spectrometry. Cancer Genomics Proteomics (2007) 0.85
Prostate cancer screening and detection in inner-city and underserved men. J Natl Med Assoc (2006) 0.85
Salvage surgery for bulky local recurrence of prostate cancer following radical prostatectomy. J Urol (2005) 0.85
Focal therapy for prostate cancer: revolution or evolution? BMC Urol (2009) 0.84
Urinary BTA: indicator of bladder cancer or of hematuria. World J Urol (2012) 0.84
The feasibility of expectant management with inner-city men with newly diagnosed localized prostate cancer. J Health Care Poor Underserved (2008) 0.83
Urinary biomarkers of bladder cancer: an update and future perspectives. Biomark Med (2013) 0.83